SCHEMBL10381095

SCHEMBL10381095

C[C@]12CC[C@H](O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(=O)CO)CC[C@@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
G6PD P11413 11/20 1.00
CYP3A4 P08684 4/20 1.00
CYP1A2 P05177 2/20 1.00
CYP2C9 P11712 2/20 1.00
PMP22 Q01453 2/20 1.00
KMT2A Q03164 2/20 1.00
TSHR P16473 1/20 1.00
ALDH1A1 P00352 1/20 1.00
MAPT P10636 1/20 1.00
GABRP O00591 2/20 0.74
GABRD O14764 2/20 0.74
GABRA1 P14867 2/20 0.74
GABRB1 P18505 2/20 0.74
GABRG2 P18507 2/20 0.74
GABRB3 P28472 2/20 0.74
GABRA5 P31644 2/20 0.74
GABRA3 P34903 2/20 0.74
GABRA2 P47869 2/20 0.74
GABRB2 P47870 2/20 0.74
GABRA4 P48169 2/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19229447 1.00 G6PD (1.00) G6PDCYP3A4CYP1A2CYP2C9PMP22
SCHEMBL20781183 1.00 G6PD (1.00) G6PDCYP3A4CYP1A2CYP2C9PMP22
SCHEMBL642973 1.00 G6PD (1.00) G6PDCYP3A4CYP1A2CYP2C9PMP22
SCHEMBL5496387 1.00 G6PD (1.00) G6PDCYP3A4CYP1A2CYP2C9PMP22
SCHEMBL21645690 1.00 G6PD (1.00) G6PDCYP3A4CYP1A2CYP2C9PMP22
SCHEMBL22593890 1.00 G6PD (1.00) G6PDCYP3A4CYP1A2CYP2C9PMP22
SCHEMBL17776488 1.00 G6PD (1.00) G6PDCYP3A4CYP1A2CYP2C9PMP22
SCHEMBL4557082 1.00 G6PD (1.00) G6PDCYP3A4CYP1A2CYP2C9PMP22
SCHEMBL18373713 1.00 G6PD (1.00) G6PDCYP3A4CYP1A2CYP2C9PMP22
SCHEMBL597740 1.00 G6PD (1.00) G6PDCYP3A4CYP1A2CYP2C9PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 919 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250100888-A1 FLUIDIC EXFOLIATION IMPERIAL COLLEGE INNOVATIONS LTD (GB) 2025-03-27 US claimed
CN-119042864-A Control method for preventing exhaust temperature of low-temperature EVI heat pump chiller from being too low 浙江中广电器集团股份有限公司 2024-11-29 CN claimed
US-12117390-B2 Method and apparatus for monitoring production of a material in a liquid dispersion in real time IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2024-10-15 US claimed
CN-118548130-A Method and device for determining engine oil dilution degree, storage medium and electronic equipment 潍柴动力股份有限公司 2024-08-27 CN claimed
US-20220260483-A1 METHOD AND APPARATUS FOR MONITORING PRODUCTION OF A MATERIAL IN A LIQUID DISPERSION IN REAL TIME IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2022-08-18 US claimed
CN-114901754-A Methods and compositions for producing graphene polyurethane foams 普世物料公司 2022-08-12 CN claimed
EP-4034600-A1 METHODS AND COMPOSITIONS FOR PRODUCING GRAPHENE POLYURETHANE FOAMS Universal Matter Inc. (CA) 2022-08-03 EP claimed
CN-113090367-B Control method and system for rapidly realizing DPF active regeneration 东风商用车有限公司 2022-07-05 CN claimed
CN-114585910-A Method and apparatus for real-time monitoring of production of materials in liquid dispersions 帝国理工创新有限公司 2022-06-03 CN claimed
EP-4003912-A1 METHOD AND APPARATUS FOR MONITORING PRODUCTION OF A MATERIAL IN A LIQUID DISPERSION IN REAL TIME Imperial College Innovations Limited (GB) 2022-06-01 EP claimed
CN-113374564-B Automobile exhaust after-treatment method 天津大学 2022-03-15 CN claimed
US-20190290659-A1 INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS ICHOR, LLC 2019-09-26 US claimed
EP-3542160-A1 INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS Ichor, LLC. (US) 2019-09-25 EP claimed
WO-2018093856-A1 INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS GUPTE SACHIN A (US) 2018-05-24 WO claimed
US-12641492-B2 UE group based cell reselection TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) 2026-05-26 US disclosed
CN-113455083-B Multiple resource allocation pattern configuration LENOVO (SINGAPORE) PTE. LTD. (SG) 2026-05-26 CN disclosed
WO-2026106519-A1 METHODS AND DEVICES FOR FACILITATING AN INTER-RAT HANDOVER TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) 2026-05-21 WO disclosed
EP-3542160-A1 INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS Ichor, LLC. (US) 2019-09-25 EP disclosed
WO-2018093856-A1 INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS GUPTE SACHIN A (US) 2018-05-24 WO disclosed
WO-1990005528-A2 ANTI-THROMBOTIC STEROIDS CHILDREN'S MEDICAL CENTER CORPORATION (US) 1990-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12641492-B2 UE group based cell reselection NUDC, PRRC2C, SET G6PD 3871/4885CYP3A4 4372/4885CYP1A2 4421/4885
US-20190290659-A1 INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS G6PD, G6PC1, UGDH G6PD 1/4885CYP3A4 714/4885CYP1A2 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.